<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>
<document xmlns:voc="http://www.hl7.org/v3/voc" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="98E72B58-1876-5C1E-9132-84C7D64D24EB" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title mediaType="text/x-hl7-title+xml">Halotestin<sup>&#174;</sup> CIII<br />fluoxymesterone<br />tablets, USP</title>
<effectiveTime value="20060206" />
<setId root="09BAFC2D-1893-4618-86DC-E9403407CD41" />
<versionNumber value="1" />
<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>Pharmacia and Upjohn Company</name>
   </representedOrganization>
  </assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="C99B52E4-8F98-1842-2558-4975BC01281B" />
<effectiveTime value="20060206" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0009-0014" codeSystem="2.16.840.1.113883.6.69" />
<name>Halotestin</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="2">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="2" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9JU12S4YFY" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>fluoxymesterone</name>
<activeMoiety>
<activeMoiety>
<code code="9JU12S4YFY" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>fluoxymesterone</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>fluoxymesterone</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="776XM7047L" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>calcium stearate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>corn starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>FD&amp;C Yellow No. 5</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="X045WJ989B" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sorbic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sucrose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>tragacanth</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>FD&amp;C Yellow No. 6</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0009-0014-01" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<policy classCode="DEADrugSchedule">
<code code="C48676" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIII" />
</policy>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CE"><originalText>peach</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"><originalText>ROUND</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="7" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">HALOTESTIN;2</value>
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0009-0019" codeSystem="2.16.840.1.113883.6.69" />
<name>Halotestin</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="5" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9JU12S4YFY" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>fluoxymesterone</name>
<activeMoiety>
<activeMoiety>
<code code="9JU12S4YFY" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>fluoxymesterone</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>fluoxymesterone</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="776XM7047L" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>calcium stearate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>corn starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>FD&amp;C Yellow No. 5</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="X045WJ989B" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sorbic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sucrose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>tragacanth</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>FD&amp;C Blue No. 2</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0009-0019-06" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<policy classCode="DEADrugSchedule">
<code code="C48676" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIII" />
</policy>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GREEN" xsi:type="CE"><originalText>light green</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"><originalText>ROUND</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="7" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">HALOTESTIN;5</value>
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0009-0036" codeSystem="2.16.840.1.113883.6.69" />
<name>Halotestin</name>
<formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="10">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="10" />
</numerator>
<denominator value="1">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9JU12S4YFY" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>fluoxymesterone</name>
<activeMoiety>
<activeMoiety>
<code code="9JU12S4YFY" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>fluoxymesterone</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>fluoxymesterone</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="776XM7047L" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>calcium stearate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>corn starch</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>FD&amp;C Yellow No. 5</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>lactose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="X045WJ989B" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sorbic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sucrose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>tragacanth</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>FD&amp;C Blue No. 2</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator value="30">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="30" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0009-0036-03" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator value="100">
<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0009-0036-04" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<subjectOf>
<policy classCode="DEADrugSchedule">
<code code="C48676" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIII" />
</policy>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GREEN" xsi:type="CE"><originalText>GREEN</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="2" xsi:type="INT" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"><originalText>ROUND</originalText></value>
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255" />
<value unit="mm" value="7" xsi:type="PQ" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255" />
<value value="false" xsi:type="BL" />
</characteristic>
</subjectOf>
<subjectOf>
<characteristic classCode="OBS">
<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255" />
<value xsi:type="ST">HALOTESTIN;10</value>
</characteristic>
</subjectOf>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section>
<id root="7BB7D32D-6E89-7F8B-E98C-7ECB16E65631" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph>HALOTESTIN Tablets contain fluoxymesterone, an androgenic hormone.</paragraph><paragraph>Fluoxymesterone is a white or nearly white, odorless, crystalline powder, melting at or about 240&#176; C, with some decomposition. It is practically insoluble in water, sparingly soluble in alcohol, and slightly soluble in chloroform.</paragraph><paragraph>The chemical name for fluoxymesterone is androst-4-en-3-one, 9-fluoro-11,17-dihydroxy-17-methyl-, (11&#946;,17&#946;)-. The molecular formula is C<sub>20</sub>H<sub>29</sub>FO<sub>3</sub> and the molecular weight 336.45.</paragraph><paragraph>The structural formula is represented below:</paragraph><renderMultiMedia referencedObject="MM1" /><paragraph>Each HALOTESTIN tablet, for oral administration, contains 2 mg, 5 mg or 10 mg fluoxymesterone. Inactive ingredients: calcium stearate, corn starch, FD&amp;C Yellow No. 5, lactose, sorbic acid, sucrose, tragacanth. In addition, the <content styleCode="Bold">2 mg</content> tablet contains FD&amp;C Yellow No. 6 and the<content styleCode="Bold"> 5 mg</content> and <content styleCode="Bold">10 mg</content> contain FD&amp;C Blue No. 2.</paragraph></text>
<effectiveTime value="20060206" />
<component>
<observationMedia ID="MM1">
<value mediaType="image/jpeg" xsi:type="ED"><reference value="halotestin-image01.jpg" /></value>
</observationMedia>
</component>
<component>
<observationMedia ID="MM2">
<value mediaType="image/jpeg" xsi:type="ED"><reference value="halotestin-image02.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section>
<id root="A9D9FCC5-44D2-4ED7-32F5-C7CC1F4E7ABE" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text><paragraph>Endogenous androgens are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of the prostate, seminal vesicles, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution. Drugs in this class also cause retention of nitrogen, sodium, potassium, and phosphorus, and decreased urinary excretion of calcium. Androgens have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.</paragraph><paragraph>Androgens are responsible for the growth spurt of adolescence and for eventual termination of linear growth, brought about by fusion of the epiphyseal growth centers. In children, exogenous androgens accelerate linear growth rates, but may cause disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of the growth process. Androgens have been reported to stimulate production of red blood cells by enhancing production of erythropoietic stimulation factor.</paragraph><paragraph>During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone
(FSH).</paragraph><paragraph>Inactivation of testosterone occurs primarily in the liver.</paragraph><paragraph>The half-life of fluoxymesterone after oral administration is approximately 9.2 hours.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="B9E9D980-008B-738D-8C03-D11BE9B5CA1E" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS &amp; USAGE SECTION" />
<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text><paragraph><content styleCode="Bold">In the male</content>&#8212;HALOTESTIN Tablets are indicated for</paragraph><list listType="ordered"><item>Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone.<list listType="ordered" styleCode="LittleAlpha"><item>Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy.</item><item>Hypogonadotropic hypogonadism (congenital or acquired)&#8212;idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.</item></list></item><item>Delayed puberty, provided it has been definitely established as such, and is not just a familial trait.</item></list><paragraph><content styleCode="Bold">In the female</content>&#8212;HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section ID="Contraindications">
<id root="EC56F679-CCD8-8CA7-898C-784949C2B9F9" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph /><list listType="ordered"><item> Known hypersensitivity to the drug</item><item> Males with carcinoma of the breast</item><item> Males with known or suspected carcinoma of the prostate gland</item><item>Women known or suspected to be pregnant</item><item>Patients with serious cardiac, hepatic or renal disease</item></list></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section ID="Warnings">
<id root="0AEA4848-E67C-1DA8-3B29-1526AA79BA79" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION" />
<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text><paragraph>Hypercalcemia may occur in immobilized patients and in patients with breast cancer. If this occurs, the drug should be discontinued.</paragraph><paragraph>Prolonged use of high doses of androgens (principally the 17-&#945;
 alkyl-androgens) has been associated with development of hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis&#8212;all potentially life-threatening complications.</paragraph><paragraph>Cholestatic hepatitis and jaundice may occur with 17-&#945;-alkyl-androgens. Should this occur, the drug should be discontinued. This is reversible with discontinuation of the drug.</paragraph><paragraph>Geriatric patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking.</paragraph><paragraph>Edema, with or without congestive heart failure, may be a serious complication
in patients with pre-existing cardiac, renal or hepatic disease.</paragraph><paragraph>Gynecomastia may develop and occasionally persists in patients being treated for hypogonadism.</paragraph><paragraph>Androgen therapy should be used cautiously in males with delayed puberty. Androgens can accelerate bone maturation without producing compensatory gain in linear growth. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.</paragraph><paragraph>This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="AA22CD87-667A-284D-A0C0-A411A09250BE" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<text />
<effectiveTime value="20060206" />
<component>
<section>
<id root="511A26B1-5C37-3E28-6465-35443CCA25D8" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GENERAL PRECAUTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">General</title>
<text><paragraph>Women should be observed for signs of virilization which is usual following androgen
use at high doses. Discontinuation of drug therapy at the time of evidence of mild virilism is necessary to prevent irreversible virilization. A decision may be made by the patient and the physician that some virilization will be tolerated during treatment for breast carcinoma.</paragraph><paragraph>Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized.</paragraph><paragraph>This product contains FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin
hypersensitivity.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="9CF8ADA5-BC40-60C3-8040-A9EA92899EE4" />
<code code="34076-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INFORMATION FOR PATIENTS SECTION" />
<title mediaType="text/x-hl7-title+xml">Information for patients</title>
<text><paragraph>Patients should be instructed to report any of the following: nausea, vomiting, changes in skin color, and ankle swelling. Males should be instructed to report too frequent or persistent erections of the penis and females any hoarseness, acne, changes in menstrual periods or increase in facial hair.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="813ECC0F-9F1D-1CBF-E9E8-4B50FCBBED73" />
<code code="34075-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="LABORATORY TESTS SECTION" />
<title mediaType="text/x-hl7-title+xml">Laboratory tests</title>
<text><paragraph>Women with disseminated breast carcinoma should have frequent determination
of urine and serum calcium levels during the course of androgen therapy (See <linkHtml href="#Warnings">WARNINGS</linkHtml>).</paragraph><paragraph>Because of the hepatotoxicity associated with the use of 17-alpha-alkylated androgens, liver function tests should be obtained periodically.</paragraph><paragraph>Periodic (every six months) X-ray examinations of bone age should be made during treatment of prepubertal males to determine the rate of bone maturation and the effects of androgen therapy on the epiphyseal centers.</paragraph><paragraph>Hemoglobin and hematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long-term androgen administration.</paragraph><paragraph>Serum cholesterol may increase during androgen therapy.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="53FF0CDB-DB20-9B3E-A061-1BFC79A13A81" />
<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG INTERACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">Drug interactions</title>
<text><paragraph>Androgens may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant
may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.</paragraph><paragraph>Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.</paragraph><paragraph>In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, insulin requirements.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="E1D68C8B-CDF9-5FE6-2EC9-D34DCF8D0673" />
<code code="34074-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG &amp;OR LABORATORY TEST INTERACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">Drug/Laboratory test interferences</title>
<text><paragraph>Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="7A3A6040-86B8-2F91-5F02-2D9F8F9498D6" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" />
<title mediaType="text/x-hl7-title+xml">Carcinogenesis, mutagenesis, impairment Of Fertility</title>
<text><paragraph>Animal data: Testosterone has been tested by subcutaneous injection and
implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically-induced carcinomas of the liver in rats.</paragraph><paragraph>Human data: There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with androgens in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases.</paragraph><paragraph>Geriatric patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking.</paragraph><paragraph>This compound has not been tested for mutagenic potential. However, as noted above, carcinogenic effects have been attributed to treatment with androgenic hormones. The potential carcinogenic effects likely occur through a hormonal mechanism rather than by a direct chemical interaction mechanism.</paragraph><paragraph>Impairment of fertility was not tested directly in animal species. However, as noted below under Adverse Reactions, oligospermia in males and amenorrhea in females are potential adverse effects of  treatment with HALOTESTIN Tablets. Therefore, impairment of fertility is a possible outcome of treatment with HALOTESTIN.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="3B9E3BF6-7FD3-414C-F5DC-4F492969F553" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title mediaType="text/x-hl7-title+xml">Pregnancy</title>
<effectiveTime value="20060206" />
<component>
<section>
<id root="D955D2E5-AC3C-43A2-9B50-96DAC543D8CF" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="TERATOGENIC EFFECTS SECTION" />
<title mediaType="text/x-hl7-title+xml">Teratogenic effects</title>
<text><paragraph>Pregnancy Category X. (See <linkHtml href="#Contraindications">CONTRAINDICATIONS</linkHtml>.)</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="E4A5BAE3-3756-8035-D012-09FF3DCF311B" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION" />
<title mediaType="text/x-hl7-title+xml">Nursing mothers</title>
<text><paragraph>HALOTESTIN is not recommended for use in nursing mothers.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="FF14BFBF-5E23-EF55-7F0B-12E5947F449A" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION" />
<title mediaType="text/x-hl7-title+xml">Pediatric use</title>
<text><paragraph>Androgen therapy should be used very cautiously in children and only by specialists aware of the adverse effects on bone maturation. Skeletal maturation must be monitored every six months by an X-ray of the hand and wrist (See <linkHtml href="#Warnings">WARNINGS</linkHtml>).</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="C48E80C1-B5D2-E396-BD98-C720AC94E1FF" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<effectiveTime value="20060206" />
<component>
<section>
<id root="EA67C5E0-C9E9-F76D-14BF-727E24DDDF53" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Endocrine and urogenital</title>
<text><paragraph>Female: the most common side effects of androgen therapy are amenorrhea and other menstrual irregularities; inhibition of gonadotropin secretion; and virilization, including deepening of the voice and clitoral enlargement. The latter usually is not reversible after androgens are discontinued. When administered to a pregnant woman, androgens can cause virilization of external genitalia of the female fetus.</paragraph><paragraph>Male: Gynecomastia, and excessive frequency and duration of penile erections. Oligospermia may occur at high dosage.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="FA70B325-743E-FA90-3118-3AC8121AF1E8" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Skin and appendages</title>
<text><paragraph>Hirsutism, male pattern of baldness, seborrhea, and acne.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="A926A55A-C653-4090-C424-DA558CEDDBBE" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Fluid and electrolyte disturbances</title>
<text><paragraph>Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="2EB4F705-0FC3-A2AF-B324-C26860C3CEFA" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Gastrointestinal</title>
<text><paragraph>Nausea, cholestatic jaundice, alterations in liver function tests, rarely hepatocellular neoplasms and peliosis hepatis (See <linkHtml href="#Warnings">WARNINGS</linkHtml>).</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="C071A0BE-C45B-9986-F8D8-E020C6D62ED8" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Hematologic</title>
<text><paragraph>Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="F9982E94-9448-0053-A534-F81FE03C3175" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Nervous system</title>
<text><paragraph>Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="7B746988-1489-AE14-66FF-E482F531A0C7" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Allergic</title>
<text><paragraph>Hypersensitivity, including skin manifestations and anaphylactoid reactions.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="28F220DC-F270-BAA7-E496-4B2425F347B2" />
<code code="42227-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG ABUSE &amp; DEPENDENCE SECTION" />
<title mediaType="text/x-hl7-title+xml">DRUG ABUSE AND DEPENDENCE</title>
<text><paragraph /></text>
<effectiveTime value="20060206" />
<component>
<section>
<id root="CE6B7460-63AA-2C91-62B6-8F8445C24AA6" />
<code code="34085-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTROLLED SUBSTANCE SECTION" />
<title mediaType="text/x-hl7-title+xml">Controlled Substance Class</title>
<text><paragraph>Fluoxymesterone is a controlled substance under the Anabolic Steroids Control Act, and HALOTESTIN Tablets has been assigned to Schedule III.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="3675B811-5DBC-394C-03D0-A47F32A84D21" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE SECTION" />
<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
<text><paragraph>There have been no reports of acute overdosage with the androgens.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="D635F1B4-D8F1-9D0E-B429-7AD58DEE923D" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE &amp; ADMINISTRATION SECTION" />
<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text><paragraph>The dosage will vary depending upon the individual, the condition being treated, and its severity. The total daily oral dose may be administered singly or in divided (three or four) doses.</paragraph></text>
<effectiveTime value="20060206" />
<component>
<section>
<id root="A322FCF2-35DD-342D-D782-E0F6E62DBDE3" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Male hypogonadism</title>
<text><paragraph>For complete replacement in the hypogonadal male, a daily dose of 5 to 20 mg will suffice in the majority of patients. It is usually preferable to begin treatment with full therapeutic doses which are later adjusted to individual requirements. Priapism is indicative of excessive dosage and is indication fortemporary withdrawal of the drug.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="80249315-FBBD-8DE8-5F66-7BFD5E061DA0" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Delayed puberty</title>
<text><paragraph>Dosage should be carefully titrated utilizing a low dose, appropriate skeletal monitoring, and by limiting the duration of therapy to four to six months.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="D84523FC-12CA-F826-FC4F-AA4161A5118F" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml">Inoperable carcinoma of the breast in the female</title>
<text><paragraph>The recommended total daily dose for palliative therapy in advanced inoperable carcinoma of the breast is 10 to 40 mg. Because of its short action, fluoxymesterone should be administered to patients in divided, rather than single, daily doses to ensure more stable blood levels. In general, it appears necessary to continue therapy for at least one month for a satisfactory subjective response, and for two to three months for an objective response.</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="DFFB1CE6-E250-CE58-31D3-20D8167E014C" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text><paragraph>HALOTESTIN Tablets, round and scored, are available in the following
strengths and colors:</paragraph><paragraph><content styleCode="bold">2 mg</content> (peach)<br />&#160;&#160;Bottles of 100&#160;&#160;&#160;&#160;&#160;&#160; NDC 0009-0014-01</paragraph><paragraph><content styleCode="bold">5 mg</content> (light green)<br />&#160;&#160;Bottles of 100&#160;&#160;&#160;&#160;&#160;&#160; NDC 0009-0019-06</paragraph><paragraph><content styleCode="bold">10 mg</content> (green)<br />&#160;&#160;Bottles of 30&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; NDC 0009-0036-03<br />&#160;&#160;Bottles of 100&#160;&#160;&#160;&#160;&#160;&#160; NDC 0009-0036-04</paragraph><paragraph>Store at controlled room temperature 20&#176; to 25&#176;C (68&#176; to 77&#176;F) [see USP].</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
<component>
<section>
<id root="E38B57EF-D6C7-064A-5779-9DAB64A80B40" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph><content styleCode="bold">Rx only</content></paragraph><renderMultiMedia referencedObject="MM2" /><paragraph>810 804 708</paragraph><paragraph>692851</paragraph><paragraph>May 2002</paragraph></text>
<effectiveTime value="20060206" />
</section>
</component>
</structuredBody>
</component>
</document>
